A Review on the Chemical versus Alternative Treatments of Leukemia

  • Aliya Fatima Mirza Department of Biological Sciences, University of Toronto, Toronto, Canada
Keywords: Leukemia; Alternative medicine; Traditional medicine; Herbal medicine; Pharmaceutical lead compounds


Common treatments for Leukemia, such as chemotherapy, have played a key role in the treatment of this life-threatening disease. However, they are associated with many side effects such as cardiovascular diseases, ocular diseases, lung toxicity, and endocrine dysfunction. The adverse effects of the common treatments are aggressive for elderly patients and patients who are unable to tolerate the treatments, resulting in their lower survival rate. Thus, more than ever before, Leukemia patients are now turning to complementary and alternative treatments. The objective of this study was to review recent literature to compare common and traditional treatments based on efficacy and associated side effects. Chemotherapy and radiation therapy are associated with many side effects, as is stem cell transplantation, which often accompanies these two treatments. Not many studies have been done on alternative, traditional treatments; however, a small number of studies showed that traditional medicine are effective in vitro. Thus, more scientific studies and clinical trials are needed to be done on alternative treatments to find the efficacy, potency and safety of their associated medicines and procedures. As medicinal concepts of the alternative, traditional treatments usually differ from the common medical treatments—although they both have the same curative goal—greater research and communication between traditional medical researchers and practitioners in alternative therapeutic traditions may lead to new and effective medicine with fewer side effects.


Kampen KR. The discovery and early understanding of leukemia. Leuk Res 2012;36:6-13.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.

DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014;64:252-271.

Blumenreich MS. The white blood cell and differential count. Clin Methods Hist Phys Lab Exam [Internet] 3rd Bost Butterworths 1990.

Bernard S, Abdelsamad E, Johnson P, Chapman D, Parvathaneni M. Pediatric Leukemia: Diagnosis to Treatment–A Review. J Cancer Clin Trials 2017;2:2.

Belson M, Kingsley B, Holmes A. Risk factors for acute leukemia in children: a review. Environ Health Perspect 2007;115:138.

D’Arena G, Laurenti L, Coscia M, Cortelezzi A, Chiarenza A, Pozzato G, et al. Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey. Leuk Lymphoma 2014;55:841-847.

Hensel M, Zoz M, Ho AD. Complementary and alternative medicine in patients with chronic lymphocytic leukemia. Support Care Cancer 2009;17:47.

Gupta M, Shafiq N, Kumari S, Pandhi P. Patterns and perceptions of complementary and alternative medicine (CAM) among leukaemia patients visiting haematology clinic of a north Indian tertiary care hospital. Pharmacoepidemiol Drug Saf 2002;11:671-676.

Chen Y-C, Lin KH. Chemotherapy-related side effects in children with acute lymphocytic leukemia in Taiwan: a nursing perspective. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1992;33:119-129.

Fraunfelder FW, Solomon J, Druker BJ, Esmaeli B, Kuyl J. Ocular side-effects associated with imatinib mesylate (Gleevec®). J Ocul Pharmacol Ther 2003;19:371-375.

Glass CK, Mitchell RN. Winning the battle, but losing the war: mechanisms and morphology of cancer-therapy-associated cardiovascular toxicity. Cardiovasc Pathol 2017;30:55-63.

Moslehi JJ, Deininger M. Tyrosine kinase inhibitor–associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol 2015;33:4210.

Sun A, Akin RS, Cobos E, Smith J. Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor. J drugs dermatology JDD 2009;8:395-398.

Guignabert C, Phan C, Seferian A, Huertas A, Tu L, Thuillet R, et al. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest 2016;126:3207-3218.

Weatherald J, Chaumais M-C, Savale L, Jaïs X, Seferian A, Canuet M, et al. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. Eur Respir J 2017;50:1700217.

Minami M, Matsumoto S, Horiuchi H. Cardiovascular side-effects of modern cancer therapy. Circ J 2010;74:1779-1786.

Kim TD, Le Coutre P, Schwarz M, Grille P, Levitin M, Fateh-Moghadam S, et al. Clinical cardiac safety profile of nilotinib. Haematologica 2012;2011.058776.

Schloemer NJ, Brickler M, Hoffmann R, Pan A, Simpson P, McFadden V, et al. Administration of dexrazoxane improves cardiac indices in children and young adults with acute myeloid leukemia (AML) while maintaining survival outcomes. J Pediatr Hematol Oncol 2017;39:e254-e258.

Hamo CE, Bloom MW. Getting to the heart of the matter: an overview of cardiac toxicity related to cancer therapy. Clin Med Insights Cardiol 2015;9:CMC S19704.

Wendtner CM, Gregor M. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia. Leuk Lymphoma 2017;1-11.

van Brussel M, Takken T, Net J van der, Engelbert RHH, Bierings M, Schoenmakers MAGC, et al. Physical function and fitness in long-term survivors of childhood leukaemia. Pediatr Rehabil 2006;9:267-274.

Sugiyama K. Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Basic Results and Pharmacokinetics. In: Chemotherapy for Leukemia. Springer; 2017. pp 79-98.

Brown JR, Hallek MJ, Pagel JM. Chemoimmunotherapy versus targeted treatment in chronic lymphocytic leukemia: when, how long, how much, and in which combination? In: American Society of Clinical Oncology educational book American Society of Clinical Oncology Meeting. 2016. pp e387-98.

Hong RA, Iimura T, Sumida KN, Eager RM. Cardio‐Oncology/Onco‐Cardiology. Clin Cardiol 2010;33:733-737.

Duffner PK. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist 2004;10:293-310.

Lennard AL, Jackson GH. Topic in Review: Stem cell transplantation. West J Med 2001;175:42.

Lennard AL, Jackson GH, Li J, Lu CC, Jiang M, Niu X, et al. Complementary and alternative medicine in patients with chronic lymphocytic leukemia. CA Cancer J Clin 2015;10:988-996.

Bhatia S, Francisco L, Carter A, Sun C-L, Baker KS, Gurney JG, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007;110:3784-3792.

Mohty B, Mohty M. Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update. Blood Cancer J 2011;1:e16.

Labbé A-C, Su SH, Laverdière M, Pépin J, Patiño C, Cohen S, et al. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation. Biol Blood Marrow Transplant 2007;13:1192–1200.

Hood AF, Vogelsang GB, Black LP, Farmer ER, Santos GW. Acute graft-vs-host disease: development following autologous and syngeneic bone marrow transplantation. Arch Dermatol 1987;123:745-750.

Har-Noy M. Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match Alternative to Allogeneic Transplant for Blood Cancers 2016.

Murshid A, Gong J, Stevenson MA, Calderwood SK. Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come. Expert Rev Vaccines 2011;10:1553-1568.

Luk A. From Leukemia to cancer-free: how CAR-T immunotherapy saved Emily Whitehead [Internet]. Available from: https://www.parkerici.org/2017/08/30/leukemia-cancer-free-how-car-t-immunotherapy-saved-emily-whitehead/

CAR T-Cell Therapies [Internet]. Available from: https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/car-t-cell1.html

Lichtenegger FS, Krupka C, Haubner S, Köhnke T, Subklewe M. Recent developments in immunotherapy of acute myeloid leukemia. J Hematol Oncol 2017;10:142.

Emami SA, Sahebkar A, Tayarani-Najaran N, Tayarani-Najaran Z. Cancer and its treatment in main ancient books of Islamic Iranian traditional medicine (7th to 14th Century AD). Iran Red Crescent Med J 2012;14:747.

Bhikha R. Theoretical Principles of Tibb. LAP LAMBERT Academic Publishing is a trademark of International Book Market Service Ltd., member of OmniScriptum Publishing Group; 2018. pp 35-44.

Zeinalian M, Eshaghi M, Naji H, Marandi SMM, Sharbafchi MR, Asgary S. Iranian-Islamic traditional medicine: An ancient comprehensive personalized medicine. Adv Biomed Res 2015;4:3-7.

Jiménez-Medina E, Garcia-Lora A, Paco L, Algarra I, Collado A, Garrido F. A new extract of the plant Calendula officinalis produces a dual in vitro effect: cytotoxic anti-tumor activity and lymphocyte activation. BMC Cancer 2006;6:119.

Miyoshi N, Nakamura Y, Ueda Y, Abe M, Ozawa Y, Uchida K. Dietary ginger constituents, galanals A and B, are potent apoptosis inducers in Human T lymphoma Jurkat cells. Cancer Lett 2003;199:113-119.

Campos JF, de Castro DTH, Damião MJ, Torquato V, Heron F, Paredes-Gamero EJ. The chemical profile of Senna velutina leaves and their antioxidant and cytotoxic effects. Oxid Med Cell Longev 2016;2016.

Zhao T, Sun Q, Marques M, Witcher M. Anticancer properties of Phyllanthus emblica (Indian gooseberry). Oxid Med Cell Longev 2015;2015.

Belapurkar P, Goyal P, Tiwari-Barua P. Immunomodulatory effects of Triphala and its individual constituents: A review. Indian J Pharm Sci 2014;76:467.

Zeinalian M, Eshaghi M, Hadian M, Naji H, Marandi SMM, Asgary S. Eight essential foods in Iranian traditional medicine and their role in health promotion and well-being. Int J Prev Med 2017;8:42-44.

Fleischer T, Chang T, Chiang J, Chang C, Hsieh C, Yen H. Adjunctive Chinese Herbal Medicine therapy improves survival of patients with chronic myeloid leukemia: a nationwide population‐based cohort study. Cancer Med 2016;5:640-648.

Fleischer T, Chang T-T, Chiang J-H, Hsieh C-Y, Sun M-F, Yen H-R. Integration of Chinese herbal medicine therapy improves survival of patients with chronic lymphocytic leukemia: a nationwide population-based cohort study. Medicine (Baltimore). 2016;95.

Miladinia M, Lamoochi Z, Lamoochi P, Zarea K, Shayesteh Fard M. Complementary and Alternative Medicine in the Pediatrics with Leukemia: A Narrative Review Study. Int J Pediatr. 2017;5:4175-4183.

Kuo Y, Yang J, Lu C, Chiang S, Lin J, Chung J. Ethanol extract of Hedyotis diffusa willd upregulates G0/G1 phase arrest and induces apoptosis in human leukemia cells by modulating caspase cascade signaling and altering associated genes expression was assayed by cDNA microarray. Environ Toxicol 2015;30:1162-1177.

Li J, Lu C, Jiang M, Niu X, Guo H, Li L, et al. Traditional chinese medicine-based network pharmacology could lead to new multicompound drug discovery. Evidence-Based Complement Altern Med 2012;2012.

Gupta M, Shaw BP. Uses of medicinal plants in Panchakarma Ayurvedic therapy 2009.

Prakash B, Parikh PM, Pal SK. Herbo-mineral ayurvedic treatment in a high risk acute promyelocytic leukemia patient with second relapse: 12 years follow up. J Ayurveda Integr Med 2010;1:215.

Prakash B. Treatment of relapsed undifferentiated acute myeloid leukemia (AML-M0) with Ayurvedic therapy. Int J Ayurveda Res 2011;2:56.

Sharma M, Porte SM. Role of ayurvedain management of leukemia (Raktarbuda). Int J Pharm Sci Res 2016;7:520-530.

Frenkel M, Sapire K. Complementary and Integrative Medicine in Hematologic Malignancies: Questions and Challenges. Curr Oncol Rep 2017;19:79.

Singh Y, Bali C. Cannabis extract treatment for terminal acute lymphoblastic leukemia with a Philadelphia chromosome mutation. Case Rep Oncol. 2013;6:585-592.

Kim C-F, Jiang J-J, Leung K-N, Fung K-P, Bik-San Lau C. Inhibitory effects of Agaricus blazei extracts on human myeloid leukemia cells. J Ethnopharmacol 2009;122:320-326.

Khan N, Ganeshpurkar A, Dubey N, Bansal D. Immunoprophylactic potential of wheat grass extract on benzene-induced leukemia: An in vivo study on murine model. Indian J Pharmacol 2015;47:394.

O’Connor M, Guilfoyle A, Breen L, Mukhardt F, Fisher C. Relationships between quality of life, spiritual well-being, and psychological adjustment styles for people living with leukaemia: An exploratory study. Ment Heal Relig Cult 2007;10:631-647.

Pereira DB, Christian LM, Patidar S, Bishop MM, Dodd SM, Athanason R. Spiritual absence and 1-year mortality after hematopoietic stem cell transplant. Biol Blood Marrow Transplant 2010;16:1171-1179.

Altaf AR, Hansen PB. Life-threatening hyponatremia provoked by alternative treatment. An occurrence in a patient with chronic lymphocytic leukemia with no indication for treatment. Ugeskr Laeger 2007;169:4367-4368.

Ikram RRR, Ghani MKA, Abdullah N. An analysis of application of health informatics in Traditional Medicine: A review of four Traditional Medicine Systems. Int J Med Inform 2015;84:988-996.

How to Cite
Mirza A. A Review on the Chemical versus Alternative Treatments of Leukemia. Trad Integr Med. 3(3):147-161.
Review Article(s)